showed that patients with higher CD163+ M2 macrophage expression at MM diagnosis had worse progression-free survival (PFS) and OS, and achieved lower rates of complete remission (CR)/near-CR rate, particularly relapsed and aggressive MM patients (86). This evidence concerns the gene CD163 and Miyoshi myopathy.